Navigation Links
Shield Therapeutics Completes Recruitment to Pivotal Phase 3 Programme for Treatment of Iron Deficiency

LONDON, June 24, 2013 /PRNewswire/ --

Shield Therapeutics, the independent specialty mineral medicines pharmaceutical company, today announces that it has completed recruitment of patients into its pivotal Phase 3 programme of ST10 for the treatment of iron-deficient anaemia.  ST10 is a novel form of ferric iron taken orally.

Patients with inflammatory bowel disease and anaemia have been recruited and randomised when oral ferrous products have been ineffective due to intolerance and/or inadequate therapeutic benefit.  The primary endpoint of this pivotal international, multi-centre programme is haemoglobin change after 12 weeks' treatment with ST10 compared to placebo.  Subjects have been included from expert centres in Austria, Germany, Hungary and the UK and either randomised to receive 30mg of ST10 twice a day, or a matched placebo capsule.  Following the randomised treatment period there is an open-label phase that allows all patients to be treated with ST10 for an additional year.  Other iron therapies have not been permitted during the study.  

Shield Therapeutics expects to report top-line results from the study at the end of Q4 2013 and anticipates these results will provide confirmatory pivotal clinical data that may form the basis of an MAA submission to the European regulatory authorities in 2014.  The data is also expected to form part of a subsequent NDA submission in the USA.

Commenting on the study, Professor Gasche, Professor of Medicine, Medical University of Vienna, Austria said:

"Inflammatory bowel disease is one of the most prevalent diseases managed by gastroenterologists.  Approximately half of all IBD patients develop iron deficiency and that can readily progress to more severe anaemia, which is the leading cause of fatigue that debilitates day-to-day quality of life.  The oral ferrous iron preparations are often poorly tolerated, leaving intravenous iron infusions as the preferred option.  However these require significant additional patient time and healthcare resources, hence there is an urgent need for a more convenient solution which we anticipate ST10 may deliver."

Shield Founder and Chief Executive Officer, Carl Sterritt, added:

"We are very grateful to the patients for their commitment, as well as the investigators and their research staff for their hard work and considerable skill that has made this study possible.  The completion of recruitment into this pivotal trial is an important step in bringing orally dosed ST10 to market as an effective way of correcting anaemia in patients who cannot tolerate oral ferrous iron therapy and so have to rely on the higher risk option of invasive and resource-consuming intravenous administration of iron."

About Shield Therapeutics

Shield Therapeutics (, founded in 2008, is an independent specialty pharmaceutical company focused on the development and commercialisation of late-stage, mineral-derived hospital pharmaceuticals which address areas of high unmet medical need.  Shield is currently conducting pivotal Phase 3 studies of its lead asset, ST10, for the treatment of iron deficiency anaemia associated with inflammatory bowel disease and is soon to commence a Phase 3 study of ST10 for the treatment of iron deficiency anaemia in patients with chronic kidney disease.

For more information about Shield Therapeutics, please contact:
Mary-Jane Elliott / Sarah Macleod/ Hollie Vile
Tel +44(0)20-7920-2330

SOURCE Shield Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. ASSA ABLOY Door Group Announces RF Shielding Openings
2. Blue Cross Blue Shield Texas Launches "Be Covered Texas" Campaign to Raise Awareness of Individual Health Insurance Enrollment Options
3. Radiation Detection, Monitoring & Safety Market (Geiger Counter, Ionization Chamber, Scintillator, Terahertz detector, Dosimeter, Environment Monitor, Shield, Lead Apron, Eyewear & Glove) - Competitive Analysis & Global Forecasts to 2017
4. Healthcare Fraud Shield Now Offers SIU Services
5. FDA Grants Soligenix Fast Track Designation for OrbeShield(TM) for the Reduction of Mortality Associated with Gastrointestinal Acute Radiation Syndrome (GI ARS)
6. BI-LO Offers Health Giveaways With Flu Vaccinations, Encourages Community To Shield Their Health This Flu Season
7. Shield HealthCare Announces 12th Annual Caregiver Story Contest
8. Wellness Center USA, Inc. Completes Psoria-Shield Inc. Acquisition
9. Healthcare Expense Management Leader Patientco Receives $3.75M in funding led by BlueCross BlueShield Venture Partners and Sandbox Industries
10. Wellness Center USA Inc. Signs Agreement to Acquire Psoria-Shield Inc.
11. Blue Cross Blue Shield of Michigan and Blue Care Network support the Drug Enforcement Administrations Nationwide Prescription "Drug Take-Back Day"
Post Your Comments:
(Date:12/1/2015)... SAN FRANCISCO , Dec. 1, 2015  InCarda ... the development and commercialization of therapies for cardiovascular conditions ... established a subsidiary business in Australia ... clinical trial in Australia in ... with leading investigators and medical centers in ...
(Date:12/1/2015)... SALT LAKE CITY , Dec. 1, 2015  Booth ... at booth #3506 during the annual meeting of the Radiological ... Chicago this year. Based in ... Imaging Components business of Varian Medical Systems (NYSE: VAR ... high voltage connectors, ionization chambers and solid state automatic exposure ...
(Date:12/1/2015)... -- Olea Sensor Networks, a leader in intelligent sensors and analytic software for sensor network-based systems, ... real-time data collection of vital signs. Photo ... ... ... ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... ... continuing medical education (CME), today announced that the first annual School of Gastrointestinal ... , “The prevention, detection and treatment of gastrointestinal cancers are undergoing transformational change, ...
(Date:12/1/2015)... ... 01, 2015 , ... Speech and physical therapies are traditionally ... technologies and under the right circumstances, these practices can be merged. This ... to his or her therapeutic sessions, as well as gives the physical and ...
(Date:12/1/2015)... ... December 01, 2015 , ... CloudLIMS ... 2015 Golden Bridge Business Awards under the New Products and Services category for ... based sample management software that helps labs organize data and track ...
(Date:12/1/2015)... CHICAGO (PRWEB) , ... December 01, 2015 , ... ... risk quantification and optimization of adjunctive imaging is the focus of numerous abstracts ... (RSNA) meeting, November 29-December 4, 2015. Nine abstracts highlight the use of ...
(Date:12/1/2015)... ... 01, 2015 , ... SAN FRANCISCO, Calif. (December 1, 2015) ... has awarded Education and Developmental Therapies (EDT), an Applied Behavior Analysis (ABA) service ... special needs providers that excel in synthesizing the areas of clinical quality, staff ...
Breaking Medicine News(10 mins):